Loading...
•
Jun 30, 2022
Zentalis Q2 2022 Earnings Report
Reported second quarter financial results and provided an operational update.
Key Takeaways
Zentalis Pharmaceuticals reported its Q2 2022 financial results, highlighting the strengthening of its leadership team, a $25 million equity investment from Pfizer, and approximately $200.2 million in gross proceeds from a recent follow-on offering, extending the company's cash runway into 2025. The company is focusing on advancing its lead clinical candidates, ZN-c3 and ZN-d5, while discontinuing the development of ZN-c5 and ZN-e4.
Received a $25 million equity investment from Pfizer to jointly advance and expand clinical development of ZN-c3.
Raised approximately $200.2 million in gross proceeds from a recent follow-on offering, extending cash runway into 2025.
Appointed Kimberly Blackwell, M.D. as Chief Executive Officer.
Focusing resources on investigating the full potential of ZN-c3 and ZN-d5, and discontinuing the clinical development of ZN-c5 and ZN-e4.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...